# Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus

> **NCT06261021** · PHASE2 · RECRUITING · sponsor: **Innovaderm Research Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Discoid Lupus Erythematosus

## Interventions

- **DRUG:** Ruxolitinib 1.5% cream
- **PROCEDURE:** Application without occlusion in Area 1
- **PROCEDURE:** Application under occlusion at night in Area 2
- **PROCEDURE:** Application under occlusion at night in Area 1
- **PROCEDURE:** Application without occlusion in Area 2

## Key facts

- **NCT ID:** NCT06261021
- **Lead sponsor:** Innovaderm Research Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-19
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-02-28
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06261021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06261021, "Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06261021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*